Day: December 8, 2021

ATLANTA, Dec. 08, 2021 (GLOBE NEWSWIRE) — American Virtual Cloud Technologies, Inc. (AVCtechnologies) (Nasdaq: AVCT) today announced that it projects revenues of its Kandy Business Unit to grow from $14.3 million in 2020 to approximately $18.8 million in 2021 and in excess of $37 million in 2022. The significant projected growth is driven by 505% year-over-year subscriber growth (90% CAGR) from January 2019 to today. AVCtechnologies delivers a full suite of cloud-based Unified Communications as a Service (UCaaS) capabilities to its cloud customers through its carrier-grade Kandy Business Solutions including Cloud PBX, Smart Office UC Clients, Collaboration, Contact Center, and SIP Trunks. The projected annual growth of the Kandy Business Unit comes as a result of deeper penetration with existing service provider and enterprise...

WASHINGTON, Dec. 08, 2021 (GLOBE NEWSWIRE) — IBEX Limited (Nasdaq: IBEX) (the “Company”) today announces that its board of directors has authorized the repurchase of up to US$20 million of the Company’s common stock. “This announcement demonstrates our confidence in IBEX’s business and underlying intrinsic value,” said Bob Dechant, Chief Executive Officer at IBEX. “While we continue to focus on IBEX’s reinvestment opportunities and runway for growth, we believe that recent changes in the trading values of our shares have provided us with an opportunity to enhance our long-term value per share. We will continue to purchase our shares opportunistically at times when we believe our stock price does not reflect the intrinsic value of our company.” The Company’s proposed repurchases may be made from time to time through open market...

TORONTO, Dec. 08, 2021 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), a leading provider of interactive mobile proximity marketing and public security alert solutions announced the appointment of Alex Romanov as the interim Chief Executive Officer. Alex Romanov has held a variety of positions with iSIGN, most recently as Strategic Advisor to the Chief Executive Officer. Alex’s in-depth knowledge of iSIGN’s technology, combined with his longstanding relationships with iSIGN’s resellers and potential clients will prove invaluable in moving iSIGN forward with its new technology development, continued funding endeavours and attaining revenue goals. The technology team that has been working with iSIGN since June of 2021 on various improvements and enhancements to iSIGN’s existing technology...

SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled “B -cell Lymphoma Franchise Update” on Tuesday, December 14, 2021 at 8:00 AM ET. The event will highlight interim Phase 1 clinical data from the Company’s FT516 and FT596 programs for the treatment of relapsed / refractory B-cell lymphomas. The live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event. The...

New York, NY, Dec. 08, 2021 (GLOBE NEWSWIRE) — Integrated Wellness Acquisition Corp (the “Company”) today announced the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (“NYSE”) and will begin trading tomorrow, Thursday, December 9, 2021, under the ticker symbol “WEL.U”. Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on NYSE under the symbols “WEL” and “WEL WS,” respectively. The offering is expected to close on December 13, 2021, subject to...

Growth Equity expands Patria’s coverage of the private markets investment spectrum and the agreement with Kamaroopin secures a partnership with a highly skilled investment team GRAND CAYMAN, Cayman Islands, Dec. 08, 2021 (GLOBE NEWSWIRE) — Patria Investments (“Patria”) (NASDAQ: PAX), a global alternative asset manager, announced today the launch of a new Growth Equity strategy, anchored by Kamaroopin, a private markets investment group previously affiliated with Tarpon Investments and led by Pedro Faria. The partnership is structured in two stages, first establishing a minority stake during a joint fundraising campaign, and then a full business combination contingent on fundraising success and certain other requirements. “Growth Equity is highly complementary to our flagship private equity business, and expands our product offering...

SILVER SPRING, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (the “Company”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the closing of the previously announced private investment in public equity (PIPE) financing. The Company received aggregate gross proceeds of approximately $14.0 million, before deducting offering expenses. The PIPE financing was led by a fund affiliated with Birchview Capital, with participation from existing investors including funds affiliated with Deerfield Management Company and HighCape Capital. “We were pleased to see the support from Birchview Capital and our existing investors,” said Ron Lloyd, the Company’s President and CEO. “These proceeds will...

TORONTO, Dec. 08, 2021 (GLOBE NEWSWIRE) — Greenhawk Resources Inc. (formerly Cryptologic Corp.) (“Greenhawk” or the “Company”) (CSE: GRHK) wishes to announce that Greg McKenzie, CEO, and Tom English, Director, have collectively acquired 22,000,000 common shares in the capital of the Company (the “Acquired Shares”) at a price of $0.045 per Acquired Share for an aggregate purchase price of $990,000 (the “Share Purchase”). The Acquired Shares were purchased in a private transaction with Greenland Resources Inc. (“Greenland”) pursuant to the private agreement exemption from the formal take-over bid requirements of National Instrument 62-104 – Take-Over Bids and Issuer Bids, on the basis that the Acquired Shares were acquired from less than five vendors at a purchase price not exceeding 115% of the then market price of the...

With an own sales office JLT strengthens its local presence in the French market, which has grown to become one of the largest and most important regions in Europe for JLT Växjö, Sweden, 8 Dec 2021 * * * JLT Mobile Computers, a leading supplier of reliable computers for demanding environments, today announced that they have signed the agreement to acquire of ID Work, their French sales partner with effect from January 2022. Since its start in 2013 ID Work has successfully been driving sales in France through a country-wide network consisting of system integrators and resellers. Since then, the French market has grown to become one of JLT’s largest and most important markets in Europe. JLT will be taking over the business and establish a local sales office with own personnel. Through the acquisition JLT will get closer to its customers...

New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthmaDupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma Published results reinforce well-established safety profile of Dupixent Positive data formed the basis for FDA approval of Dupixent in these patients with certain types of moderate-to-severe asthma and regulatory reviews are ongoing in the European UnionPARIS and TARRYTOWN, N.Y. – December 8, 2021 – The New England Journal of Medicine has published positive results from a pivotal Dupixent® (dupilumab) clinical trial in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. These data formed the basis for the...